Haemonetics (HAE) Given Daily News Sentiment Score of 0.17

Media headlines about Haemonetics (NYSE:HAE) have trended somewhat positive this week, according to Accern. The research firm identifies negative and positive media coverage by analyzing more than 20 million news and blog sources in real time. Accern ranks coverage of companies on a scale of negative one to one, with scores nearest to one being the most favorable. Haemonetics earned a daily sentiment score of 0.17 on Accern’s scale. Accern also assigned media headlines about the medical instruments supplier an impact score of 45.4327994617882 out of 100, indicating that recent media coverage is somewhat unlikely to have an impact on the stock’s share price in the next few days.

These are some of the media headlines that may have impacted Accern Sentiment Analysis’s scoring:

Shares of Haemonetics (HAE) opened at $74.28 on Thursday. Haemonetics has a 12 month low of $38.43 and a 12 month high of $75.45. The company has a quick ratio of 1.33, a current ratio of 1.82 and a debt-to-equity ratio of 0.14. The firm has a market capitalization of $3,949.77, a price-to-earnings ratio of -218.46, a P/E/G ratio of 3.66 and a beta of 0.92.

Haemonetics (NYSE:HAE) last posted its quarterly earnings results on Tuesday, February 6th. The medical instruments supplier reported $0.62 earnings per share for the quarter, beating analysts’ consensus estimates of $0.44 by $0.18. Haemonetics had a positive return on equity of 12.39% and a negative net margin of 1.94%. The business had revenue of $234.04 million for the quarter, compared to analysts’ expectations of $227.79 million. During the same quarter in the prior year, the business earned $0.43 EPS. The firm’s revenue for the quarter was up 2.7% on a year-over-year basis. equities analysts expect that Haemonetics will post 1.86 earnings per share for the current year.

Haemonetics announced that its board has authorized a share repurchase plan on Tuesday, February 6th that allows the company to repurchase $260.00 million in outstanding shares. This repurchase authorization allows the medical instruments supplier to buy shares of its stock through open market purchases. Stock repurchase plans are often an indication that the company’s management believes its shares are undervalued.

Several equities research analysts have recently commented on the company. TheStreet downgraded Haemonetics from a “b” rating to a “c+” rating in a report on Tuesday, February 6th. ValuEngine raised Haemonetics from a “hold” rating to a “buy” rating in a report on Thursday, March 1st. Zacks Investment Research raised Haemonetics from a “hold” rating to a “buy” rating and set a $78.00 price objective for the company in a report on Friday, February 9th. Morgan Stanley increased their price objective on Haemonetics from $74.00 to $77.00 and gave the company an “overweight” rating in a report on Wednesday, February 7th. Finally, Barrington Research reissued an “outperform” rating and issued a $71.00 price objective (up previously from $57.00) on shares of Haemonetics in a report on Wednesday, February 7th. One analyst has rated the stock with a sell rating, two have assigned a hold rating and six have issued a buy rating to the stock. The company presently has a consensus rating of “Buy” and a consensus price target of $71.33.

In related news, Director Mark W. Kroll sold 7,118 shares of the stock in a transaction on Tuesday, January 2nd. The stock was sold at an average price of $63.00, for a total value of $448,434.00. Following the sale, the director now owns 33,881 shares in the company, valued at approximately $2,134,503. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, EVP Michelle L. Basil sold 389 shares of the stock in a transaction on Tuesday, March 6th. The shares were sold at an average price of $72.23, for a total value of $28,097.47. The disclosure for this sale can be found here. In the last 90 days, insiders sold 7,621 shares of company stock worth $484,766. 1.20% of the stock is owned by company insiders.

COPYRIGHT VIOLATION NOTICE: This story was posted by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are reading this story on another website, it was illegally copied and republished in violation of US and international copyright and trademark laws. The original version of this story can be accessed at https://www.dispatchtribunal.com/2018/03/15/haemonetics-hae-given-daily-news-sentiment-score-of-0-17.html.

Haemonetics Company Profile

Haemonetics Corporation (Haemonetics) is a healthcare company. The Company provides various products to customers involved in the processing, handling and analysis of blood. The Company’s segments include Japan, EMEA, North America Plasma and All Other. Haemonetics provides plasma collection systems and software, which enable plasma fractionators to make pharmaceuticals.

Insider Buying and Selling by Quarter for Haemonetics (NYSE:HAE)

Receive News & Ratings for Haemonetics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Haemonetics and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply